Sagimet Biosciences
SGMT
8.72
-0.16
-1.80%
Sagimet Biosciences
US · SGMT
#3599 by market cap
Listed 2023
8.72
-0.16
-1.80%
Live - 5344 symbols - heartbeat 405s ago
· 2026-10-08 10:00
Pre-market
8.83
-0.56%
After-hours
8.88
0.00%
- Market cap
- 618.32M
- P/E (TTM)i
- -6.92
- P/Bi
- 2.41
- EPSi
- -1.58
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on SGMT?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Margins
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0 | 2.00M | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.86M | 3.22M | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Research & development | 8.39M | 8.18M | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Operating profit | -14.25M | -11.40M | -23.72M | -31.06M | -30.74M | -54.45M | -56.89M |
| Pretax profit | -14.26M | -11.37M | -24.44M | -30.50M | -27.88M | -45.57M | -51.04M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -14.26M | -11.37M | -24.44M | -30.50M | -27.88M | -45.57M | -51.04M |
| Basic EPS | -1 | -1 | -1 | -1 | -3 | -1 | -2 |
| Diluted EPS | -0.64 | -0.51 | -1.10 | -1.38 | -2.66 | -1.45 | -1.58 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.52M | 4.68M | 4.60M | 4.03M | 4.72M | 4.28M |
| Research & development | 15.34M | 7.25M | 9.73M | 6.73M | 7.00M | 11.54M |
| Operating profit | -19.87M | -11.93M | -14.33M | -10.77M | -11.71M | -15.82M |
| Pretax profit | -18.18M | -10.39M | -12.91M | -9.57M | -10.65M | -13.95M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -18.18M | -10.39M | -12.91M | -9.57M | -10.65M | -13.95M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.56 | -0.32 | -0.40 | -0.29 | -0.33 | -0.26 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 10.82M | 68.74M | 58.66M | 32.79M | 96.65M | 152.77M | 116.40M |
| Cash & ST investments | 10.21M | 68.70M | 56.73M | 32.35M | 94.90M | 151.25M | 113.12M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 11.16M | 68.96M | 59.03M | 33.03M | 96.72M | 160.26M | 116.48M |
| Total current liabilities | 2.08M | 1.91M | 2.44M | 5.28M | 5.65M | 4.45M | 5.10M |
| Short-term debt | 130.00K | 145.00K | 124.00K | 133.00K | 65.00K | 78.00K | 78.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 136,475,000.00 | 204,869,000.00 | 217,291,000.00 | 219,981,000.00 | 5,654,000.00 | 4,454,000.00 | 5,101,000.00 |
| Total equity | -125.32M | -135.91M | -158.26M | -186.95M | 91.07M | 155.81M | 111.38M |
| Retained earnings | -155.56M | -166.93M | -191.37M | -221.87M | -249.74M | -295.31M | -346.35M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 146.07M | 127.20M | 119.48M | 116.40M | 107.72M | 243.99M |
| Cash & ST investments | 144.57M | 125.41M | 116.69M | 113.12M | 104.54M | 240.13M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 146.17M | 137.41M | 128.40M | 116.48M | 107.76M | 263.43M |
| Total current liabilities | 7.18M | 7.25M | 9.15M | 5.10M | 5.30M | 5.42M |
| Short-term debt | 39.00K | 152.00K | 115.00K | 78.00K | 39.00K | 84.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 7,180,000.00 | 7,247,000.00 | 9,146,000.00 | 5,101,000.00 | 5,297,000.00 | 7,275,000.00 |
| Total equity | 138.99M | 130.16M | 119.26M | 111.38M | 102.46M | 256.16M |
| Retained earnings | -313.49M | -323.87M | -336.78M | -346.35M | -357.00M | -370.95M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.55M | -10.42M | -21.71M | -24.49M | -23.77M | -42.44M | -45.65M |
| Depreciation & amortization | 1.00K | 0 | -- | -- | -- | -- | -- |
| Free cash flow | -10.55M | -10.42M | -21.71M | -24.49M | -23.77M | -42.44M | -45.65M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | 89.68M | 105.75M | 0 |
| Ending cash balance | 10.21M | 68.70M | 56.73M | 158.00K | 75.14M | 75.84M | 35.02M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -14.54M | -9.10M | -10.18M | -11.83M | -8.61M | -11.10M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -14.54M | -9.10M | -10.18M | -11.83M | -8.61M | -11.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 64.72M | 42.33M | 32.50M | 35.02M | 36.63M | 165.90M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -36.92 | -38.20 |
| ROA %i | -127.79 | -28.38 | -38.19 | -66.26 | -42.97 | -35.46 | -36.89 |
| ROIC %i | -- | -- | -- | -- | -- | -44.09 | -42.56 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -1,537.00 | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.21 | 35.99 | 24.04 | 6.21 | 17.09 | 34.30 | 22.82 |
| Quick ratioi | 4.92 | 35.97 | 23.25 | 6.13 | 16.78 | 33.96 | 22.18 |
| Debt / assetsi | 3.06 | 0.30 | 0.59 | 0.64 | 0.07 | 0.05 | 0.07 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -221.83 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | -- | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -34.72 | -37.89 | -39.78 | -38.20 | -36.04 | -24.37 |
| ROA %i | -33.53 | -36.38 | -38.04 | -36.89 | -34.27 | -23.49 |
| ROIC %i | -39.84 | -42.64 | -44.33 | -42.56 | -40.36 | -26.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 20.34 | 17.55 | 13.06 | 22.82 | 20.34 | 45.02 |
| Quick ratioi | 20.13 | 17.30 | 12.76 | 22.18 | 19.74 | 44.31 |
| Debt / assetsi | 0.03 | 0.11 | 0.09 | 0.07 | 0.04 | 0.74 |
| LT debt / equityi | -- | -- | -- | -- | -- | 0.72 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of therapeutics for the treatment of acne, metabolic dysfunction100.00%
Region
United States100.00%
Quote time 2026-10-08 10:00:18 · For reference only, not investment advice and not tailored to your situation.